nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2023-6-142-145nnp-2151Research ArticleREVIEWSОБЗОРЫOfatumumab – the first fully human monoclonal antibody approved for the treatment of multiple sclerosisОфатумумаб – первое полностью человеческое моноклональное антитело, зарегистрированное для лечения рассеянного склерозаhttps://orcid.org/0000-0003-2676-452XПоповаЕ. В.PopovaE. V.

ГБУЗ «Городская клиническая больница № 24 Департамента здравоохранения города Москвы», Москва Россия

Ekaterina Valerievna Popova

Moscow 10, Pistsovaya St., Moscow 127015

ani_retake1@mail.ruГБУЗ «Городская клиническая больница № 24 Департамента здравоохранения города Москвы», Москва РоссияРоссияCity Clinical Hospital Twenty-Four, Moscow Healthcare DepartmentRussian Federation202317122023156142145Copyright © Popova E.V., 20232023Попова Е.В.Popova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/2151

Currently, more than 15 molecules are already approved for the treatment of multiple sclerosis, and sometimes physicians encounter problems selecting a drug for therapy when considering patients with the initial equivalent characteristics. When selecting a drug, it is important to consider not only the efficacy and safety of the drug, but also the possibility of further therapy after discontinuation of the initially selected drug. This paper discusses the results of clinical trials on the efficacy and safety of ofatumumab and its potential advantages over other anti-CD20 agents.

В настоящее время для лечения рассеянного склероза зарегистрировано уже более 15 молекул, и порой клиницисты отмечают некоторые проблемы при выборе препарата для терапии при исходных равнозначных характеристиках больного. При выборе необходимо учитывать не только эффективность и безопасность выбираемого препарата, но и возможности дальнейшей терапии после прекращения приема изначально выбранного лекарственного средства. Обсуждаются результаты клинических исследований, посвященных эффективности и безопасности препарата офатумумаб, и его возможные преимущества среди других анти-CD20агентов.

рассеянный склерозофатумумабмоноклональное антителоанти-CD20-терапияmultiple sclerosisofatumumabmonoclonal antibodyanti-CD20Статья спонсируется компанией «Новартис»This article has been supported by NovartisReferencesPröbstel AK, Hauser SL. Multiple Sclerosis: B Cells Take Center Stage. J Neuroophthalmol. 2018 Jun;38(2):251-8. doi: 10.1097/WNO.0000000000000642Pröbstel AK, Hauser SL. Multiple Sclerosis: B Cells Take Center Stage. J Neuroophthalmol. 2018 Jun;38(2):251-8. doi: 10.1097/WNO.0000000000000642Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J. 2008 Oct;3(9-10):1157-71. doi: 10.1002/biot.200800110Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J. 2008 Oct;3(9-10):1157-71. doi: 10.1002/biot.200800110Frisch ES, Pretzsch R, Weber MS. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20 – Yet Progress Continues. Neurotherapeutics. 2021 Jul;18(3):1602-22. doi: 10.1007/s13311-02101048-z. Epub 2021 Apr 20.Frisch ES, Pretzsch R, Weber MS. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20 – Yet Progress Continues. Neurotherapeutics. 2021 Jul;18(3):1602-22. doi: 10.1007/s13311-02101048-z. Epub 2021 Apr 20.Klein C, Lammens A, SchКfer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013 Jan-Feb;5(1):22-33. doi: 10.4161/mabs.22771. Epub 2012 Dec 4.Klein C, Lammens A, SchКfer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013 Jan-Feb;5(1):22-33. doi: 10.4161/mabs.22771. Epub 2012 Dec 4.Hauser SL, Bar-Or A, Cohen JA, et al. B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis from the Pooled Phase 3 ASCLEPIOS I and II Trials. AAN 2020. Poster Session: P7.1-013Hauser SL, Bar-Or A, Cohen JA, et al. B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis from the Pooled Phase 3 ASCLEPIOS I and II Trials. AAN 2020. Poster Session: P7.1-013Kappos L, Bar-Or A, Cohen JA, et al. Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials. Annual Meeting of the American Academy of Neurology, 2020.Kappos L, Bar-Or A, Cohen JA, et al. Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials. Annual Meeting of the American Academy of Neurology, 2020.Hauser SL, Bar-Or A, Cohen JA, et al; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):54657. doi: 10.1056/NEJMoa1917246Hauser SL, Bar-Or A, Cohen JA, et al; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):54657. doi: 10.1056/NEJMoa1917246Scalfari A, Romualdi C, Nicholas RS, et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. Neurology. 2018 Jun 12;90(24):e2107-e2118. doi: 10.1212/WNL.0000000000005685. Epub 2018 May 16.Scalfari A, Romualdi C, Nicholas RS, et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. Neurology. 2018 Jun 12;90(24):e2107-e2118. doi: 10.1212/WNL.0000000000005685. Epub 2018 May 16.Samjoo IA, Drudge C, Walsh S, et al. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. J Comp Eff Res. 2023 Jul;12(7):e230016. doi: 10.57264/cer-2023-0016. Epub 2023 Jun 2.Samjoo IA, Drudge C, Walsh S, et al. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. J Comp Eff Res. 2023 Jul;12(7):e230016. doi: 10.57264/cer-2023-0016. Epub 2023 Jun 2.Chen C, Zhang E, Zhu C, et al. Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis. J Am Pharm Assoc (2003). 2023 Jan-Feb;63(1):8-22.e23. doi: 10.1016/j.japh.2022.07.009. Epub 2022 Aug 1.Chen C, Zhang E, Zhu C, et al. Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis. J Am Pharm Assoc (2003). 2023 Jan-Feb;63(1):8-22.e23. doi: 10.1016/j.japh.2022.07.009. Epub 2022 Aug 1.Hennessy B, Zierhut ML, Kracker H, et al. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate. Mult Scler Relat Disord. 2022 Aug;64:103908. doi: 10.1016/j.msard.2022.103908. Epub 2022 May 23.Hennessy B, Zierhut ML, Kracker H, et al. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate. Mult Scler Relat Disord. 2022 Aug;64:103908. doi: 10.1016/j.msard.2022.103908. Epub 2022 May 23.Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab vs Teriflunomide in Relapsing Multiple Sclerosis: Analysis of No Evidence of Disease Activity (NEDA-3) from ASCLEPIOS I and II Trials. Presented at EAN 2020. LB62. Abstracts_LB_210x276_V2.pdf (ean.org). Available from: https://www.ean.org/fileadmin/ user_upload/ean/congress-2020/Present/Abstracts/Abstracts_LB_210x276_V2.pdfHauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab vs Teriflunomide in Relapsing Multiple Sclerosis: Analysis of No Evidence of Disease Activity (NEDA-3) from ASCLEPIOS I and II Trials. Presented at EAN 2020. LB62. Abstracts_LB_210x276_V2.pdf (ean.org). Available from: https://www.ean.org/fileadmin/ user_upload/ean/congress-2020/Present/Abstracts/Abstracts_LB_210x276_V2.pdfDe Seze J, Bar-Or A, Correale J, et al. Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis Patients from the Phase 3 ASCLEPIOS I and II Trials. Presented at EAN 2020. LB82De Seze J, Bar-Or A, Correale J, et al. Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis Patients from the Phase 3 ASCLEPIOS I and II Trials. Presented at EAN 2020. LB82Smith P et al. Poster P401 presented at ECTRIMS 2016.Smith P et al. Poster P401 presented at ECTRIMS 2016.Smith P et al. Oral presentation S24-003 presented at AAN 2017.Smith P et al. Oral presentation S24-003 presented at AAN 2017.Theil D et al. Poster P657 presented at ECTRIMS 2017.Theil D et al. Poster P657 presented at ECTRIMS 2017.Graham G et al. Poster P0396 presented at ACTRIMSECTRIMS 2020.Graham G et al. Poster P0396 presented at ACTRIMSECTRIMS 2020.Savelieva M et al. Poster EP1624 presented at ECTRIMS 2017.Savelieva M et al. Poster EP1624 presented at ECTRIMS 2017.Ocrelizumab [prescribing information]. South San Francisco, CA: Genentech; March 2017.Ocrelizumab [prescribing information]. South San Francisco, CA: Genentech; March 2017.Rituximab [summary of product characteristics]. Germany: Roche; February 2020.Rituximab [summary of product characteristics]. Germany: Roche; February 2020.Torres JB, Roodselaar J, Sealey M, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol. 2022 Jul 28;13:814064. doi: 10.3389/fimmu.2022.814064Torres JB, Roodselaar J, Sealey M, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol. 2022 Jul 28;13:814064. doi: 10.3389/fimmu.2022.814064Wu F, Bhansali SG, Law WC, et al. Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence. Pharm Res. 2012 Jul;29(7):1843-53. doi: 10.1007/s11095-012-0708-6Wu F, Bhansali SG, Law WC, et al. Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence. Pharm Res. 2012 Jul;29(7):1843-53. doi: 10.1007/s11095-012-0708-6Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012 Sep;14(3):559-70. doi: 10.1208/s12248-0129367-0. Epub 2012 May 23.Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012 Sep;14(3):559-70. doi: 10.1208/s12248-0129367-0. Epub 2012 May 23.Migotto MA et al. P3.406 presented at AAN 2018.Migotto MA et al. P3.406 presented at AAN 2018.Usach I, Martinez R, Festini T, Peris JE. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site. Adv Ther. 2019 Nov;36(11):2986-96. doi: 10.1007/s12325-01901101-6. Epub 2019 Oct 5.Usach I, Martinez R, Festini T, Peris JE. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site. Adv Ther. 2019 Nov;36(11):2986-96. doi: 10.1007/s12325-01901101-6. Epub 2019 Oct 5.Benedetti MS, Whomsley R, Poggesi I, et al. Drug metabolism and pharmacokinetics. Drug Metab Rev. 2009;41(3):344-90. doi: 10.1080/10837450902891295Benedetti MS, Whomsley R, Poggesi I, et al. Drug metabolism and pharmacokinetics. Drug Metab Rev. 2009;41(3):344-90. doi: 10.1080/10837450902891295Bigaud M, Anthony D, Lutzenburg P, et al. Comparative Pharmacology of Ofatumumab versus Ocrelizumab in Humanised-CD20 Transgenic Mice. Presented at ECTRIMS 2022. P298. Available from: https://www.medcommshydhosting.com/MSKnowledgecenter/ectrims/2022/Abstr acts/P298_Abstract.pdfBigaud M, Anthony D, Lutzenburg P, et al. Comparative Pharmacology of Ofatumumab versus Ocrelizumab in Humanised-CD20 Transgenic Mice. Presented at ECTRIMS 2022. P298. Available from: https://www.medcommshydhosting.com/MSKnowledgecenter/ectrims/2022/Abstr acts/P298_Abstract.pdfHauser S et al. AAN 2022. Oral presentation S14.004.Hauser S et al. AAN 2022. Oral presentation S14.004.Sacca F et al. EAN 2022. Oral presentation. OPR134.Sacca F et al. EAN 2022. Oral presentation. OPR134.Sacca F et al. Poster presented at ЕAN 2023; EPO-642.Sacca F et al. Poster presented at ЕAN 2023; EPO-642.Инструкция по медицинскому применению препарата офатумумаб ЛП-№ (001332)(РГ-RU) от 25.10.2022. Доступно по ссылке: https://grls.rosminzdrav.ru/grls (дата обращения 03.11.2022).Instructions for medical use of drug ofatumumab ЛП-№(001332)-(РГ-RU) dated 10/25/2022. Available from: https://grls.rosminzdrav.ru/grls (accessed 03.11.2022) (In Russ.).Ziemssen T, Groth M, Ettle B, Bopp T. Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab. Vaccines (Basel). 2022 Dec 16;10(12):2167. doi: 10.3390/vaccines10122167Ziemssen T, Groth M, Ettle B, Bopp T. Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab. Vaccines (Basel). 2022 Dec 16;10(12):2167. doi: 10.3390/vaccines10122167

The authors declare that there are no conflicts of interest present.